Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: Do onabotulinum toxin‐A injections improve sexual function?

Abstract

AbstractIntroductionInterstitial cystitis/bladder pain syndrome (IC/BPS) has a negative impact on female sexual function. We aimed to evaluate the effect of intravesical botulinum toxin‐A (BTX‐A) injection on the improvement of sexual dysfunction and urinary symptoms using the multi‐domain female sexual function Index (FSFI), interstitial cystitis symptom index (ICSI), and interstitial cystitis problem index (ICPI).Material and MethodThe data of the 23 patients (study group) who received intravesical BTX‐A with the diagnosis of IC/BPS were reviewed. Twenty‐three age‐matched healthy, sexually active women were determined as the control group. Patients received 100 U BTX‐A submucosally injections, including the trigone. One hundred units of BTX‐A were diluted to 20 cc 0.9% saline, and 1  cc was then applied submucosally on 20 different points of the bladder wall (5 U/1 mL per site). The study group was asked to fill out FSFI, ICSI, and ICPI, as well as the visual analog scale (VAS) and bladder diary before and 3 months after the treatment. Patients in the control group completed the same questionnaires once. The pre‐ and post‐treatment questionnaire scores were compared in the study group. The study group's data were also compared to the control group.ResultsCompared to the pretreatment period, the study group showed statistically significant improvement in the total FSFI score and each domain of the FSFI after BTX‐A injection. The mean total FSFI score and three domains of FSFI (desire, lubrication, pain) reached to the score of the control group following BTX‐A injection. Statistically significant improvements were also shown in scores of ICSI, ICPI, and VAS. (p < 0.05).ConclusionIC/BPS is associated with a very high incidence of sexual dysfunction. Intravesical BTX‐A injection may provide significant improvement in sexual dysfunction in women with IC/BPS.